Credo Technology Reports 157% Revenue Growth in Q4
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: NASDAQ.COM
- Significant Revenue Growth: Credo Technology reported $437 million in revenue for Q4 2026, representing a 157% year-over-year increase, surpassing analyst expectations of $431.8 million, highlighting the company's robust performance in the AI infrastructure sector.
- Declining Profitability: Despite a net income of $226.7 million and earnings per share of $1.16, the company's profit margin slightly decreased from 68.6% to 68.3%, with projections indicating a further drop to 68% in the next quarter, which may affect investor confidence.
- Lackluster Market Reaction: Although Credo's stock surged 101% over the past three months, it fell more than 12% in after-hours trading following the earnings report, reflecting disappointment in the market's high expectations.
- Future Growth Potential: CEO Bill Brennan indicated that Credo's AEC business will serve as a core growth engine, with projections of multiple product lines each contributing over $100 million in revenue in the next fiscal year, driving overall revenue growth of over 80%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRDO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRDO
Wall Street analysts forecast CRDO stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 217.500
Low
170.00
Averages
221.82
High
260.00
Current: 217.500
Low
170.00
Averages
221.82
High
260.00
About CRDO
Credo Technology Group Holding Ltd is a Cayman Islands-based holding company. The Company delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides high-speed connectivity solutions that deliver improved power efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. Its connectivity solutions are optimized for optical and electrical Ethernet applications, including the emerging 100 gigabits per second (G), 200G, 400G, 800G and the emerging 1.6 terabits per second (T) port markets. Its products are based on its Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies. Its product families include integrated circuits (ICs) for the optical and line card markets, active electrical cables (AECs) and SerDes Chiplets. The Company’s intellectual property (IP) solutions consist primarily of SerDes IP licensing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Credo Technology Reports 157% Revenue Surge in Q4 Earnings
- Significant Revenue Growth: Credo Technology reported a remarkable 157% year-over-year revenue increase in Q4, reaching $437 million, showcasing the company's potential driven by robust AI demand, despite cautious market reactions to its guidance.
- Market Reaction Analysis: Although the stock slightly recovered post-earnings, concerns about high valuation and margin compression as the company shifts towards lower-margin optical products continue to pressure the stock price.
- Analysts' Optimistic Outlook: Many analysts view the current dip as a buying opportunity, projecting that the optical segment will generate over $600 million in revenue by fiscal 2027, indicating strong growth potential ahead.
- Customer Concentration Risk: While customer concentration risk is moderating, the top three customers still account for 77% of total revenue, leaving the company vulnerable to potential CAPEX cuts from a small group of large-scale clients.
See More
Three Underrated Investment Opportunities
- Credo Technology Group Growth: Credo reported $1.34 billion in revenue for fiscal 2026, more than tripling its 2025 results, with a gross margin of 69.43%, indicating strong demand and profitability in the AI infrastructure market.
- Cellebrite's Transformation: Cellebrite achieved a 21% increase in annual recurring revenue and a 32% free cash flow margin, successfully transitioning from perpetual software licenses to a subscription model, which is expected to enhance future revenue predictability and stability.
- TransMedics Innovation: TransMedics' Organ Care System extends organ transport time through real-time perfusion technology, with Q1 revenue rising 21% year-over-year, and full-year revenue guidance of $727 million to $757 million, showcasing its unique competitive advantage in the medical device sector.
- Market Demand and Investment Potential: These three companies possess strong market demand and growth potential in their respective fields, particularly in critical sectors like AI, law enforcement, and medical devices, making them worthy of investor attention and consideration.
See More
Three Underrated Tech Companies to Watch
- Credo's Technological Breakthrough: Credo Technology Group reported $1.34 billion in revenue for fiscal 2026, more than tripling its 2025 results with a 157% year-over-year growth in Q4, indicating strong demand in the AI infrastructure market, and expects to generate over $500 million from optical products in the future.
- Cellebrite's Market Advantage: Cellebrite serves over 60,000 law enforcement agencies across 150 countries, achieving a 21% growth in annual recurring revenue and a 32% free cash flow margin in its latest quarter, establishing a strong competitive position in digital evidence processing.
- TransMedics' Innovative Healthcare: TransMedics' Organ Care System revolutionizes organ transplantation with real-time perfusion technology, reporting a 21% year-over-year revenue increase to $173.9 million in Q1, and expects annual revenue between $727 million and $757 million, showcasing its unique competitive edge in the medical device sector.
- Investment Potential Analysis: These three companies, while not currently dominating financial headlines, possess significant long-term investment value due to their technological innovations and market demand, particularly in the rapidly evolving fields of AI and healthcare technology.
See More
Strong Start for June Stocks, Focus on Three Tech Giants
- Profitability Highlight: Micron Technology (MU) boasts a 41.5% net profit margin over the past 12 months, with an expected earnings growth rate of 619.8% this year, showcasing its strong competitive position in the memory and storage market, thus attracting investor interest for future growth potential.
- High-Speed Connectivity Solutions: Credo Technology (CRDO) offers high-speed connectivity solutions for Ethernet and PCIe applications, achieving a 31.8% net profit margin over the past year, with an anticipated earnings growth rate of 371.4% this year, indicating significant profitability in the rapidly evolving tech market.
- Automated Testing Systems: Teradyne (TER) excels in developing automated test systems and robotics solutions, achieving a 22.6% net profit margin over the past year, with an expected earnings growth rate of 79% this year, reflecting strong growth potential in the automation sector.
- Investment Strategy Effectiveness: Zacks' stock-picking strategies have outperformed the S&P's average gain of 7.7% per year since 2000, with average gains of 48.4%, 50.2%, and 56.7%, demonstrating their effectiveness and attractiveness in the market.
See More
Dow Jones Rises Amid Ongoing U.S.-Iran Talks; Celestica Sees Major Movement
- Dow Jones Rises: The Dow Jones index climbed on Tuesday amid ongoing U.S.-Iran talks, reflecting market optimism regarding diplomatic progress, which could enhance investor confidence and drive further stock market gains.
- Celestica's Major Movement: Celestica's stock experienced significant fluctuations, potentially linked to its latest earnings report or market dynamics, which may attract short-term traders and impact its shareholder structure.
- Nvidia's Decline: Nvidia's stock fell, likely due to market concerns about its future performance, especially in the context of increasing competition, which could affect its market share and investor confidence.
- Market Sentiment Shifts: Overall market sentiment fluctuated due to international political dynamics, prompting investors to monitor the progress of negotiations in the coming days to assess potential impacts on the stock market.
See More
Solstice and Core Scientific See Active Options Trading
- Solstice Options Volume: Solstice Advanced Materials Inc (Ticker: SOLS) saw options trading volume of 18,645 contracts today, representing approximately 1.9 million shares, which is about 79.3% of its average daily trading volume of 2.4 million shares over the past month, indicating heightened market interest in its future performance.
- High Volume Contracts: The $65 strike put option for SOLS was particularly active, with 15,892 contracts traded today, equating to approximately 1.6 million shares, reflecting investor expectations regarding potential downside risks for the stock.
- Core Scientific Options Activity: Concurrently, Core Scientific Inc (Ticker: CORZ) recorded options trading volume of 113,081 contracts, representing about 11.3 million shares, which accounts for 68.8% of its average daily trading volume of 16.4 million shares over the past month, showcasing strong market interest in its stock.
- Key Contract Insights: Among CORZ options, the $40 strike call option saw a trading volume of 25,119 contracts, approximately 2.5 million shares, indicating investor confidence in the stock's potential upside, which may influence its short-term price movements.
See More
Credo Technology Reports 157% Revenue Surge in Q4 Earnings
- Significant Revenue Growth: Credo Technology reported a remarkable 157% year-over-year revenue increase in Q4, reaching $437 million, showcasing the company's potential driven by robust AI demand, despite cautious market reactions to its guidance.
- Market Reaction Analysis: Although the stock slightly recovered post-earnings, concerns about high valuation and margin compression as the company shifts towards lower-margin optical products continue to pressure the stock price.
- Analysts' Optimistic Outlook: Many analysts view the current dip as a buying opportunity, projecting that the optical segment will generate over $600 million in revenue by fiscal 2027, indicating strong growth potential ahead.
- Customer Concentration Risk: While customer concentration risk is moderating, the top three customers still account for 77% of total revenue, leaving the company vulnerable to potential CAPEX cuts from a small group of large-scale clients.
See More
Three Underrated Investment Opportunities
- Credo Technology Group Growth: Credo reported $1.34 billion in revenue for fiscal 2026, more than tripling its 2025 results, with a gross margin of 69.43%, indicating strong demand and profitability in the AI infrastructure market.
- Cellebrite's Transformation: Cellebrite achieved a 21% increase in annual recurring revenue and a 32% free cash flow margin, successfully transitioning from perpetual software licenses to a subscription model, which is expected to enhance future revenue predictability and stability.
- TransMedics Innovation: TransMedics' Organ Care System extends organ transport time through real-time perfusion technology, with Q1 revenue rising 21% year-over-year, and full-year revenue guidance of $727 million to $757 million, showcasing its unique competitive advantage in the medical device sector.
- Market Demand and Investment Potential: These three companies possess strong market demand and growth potential in their respective fields, particularly in critical sectors like AI, law enforcement, and medical devices, making them worthy of investor attention and consideration.
See More
Three Underrated Tech Companies to Watch
- Credo's Technological Breakthrough: Credo Technology Group reported $1.34 billion in revenue for fiscal 2026, more than tripling its 2025 results with a 157% year-over-year growth in Q4, indicating strong demand in the AI infrastructure market, and expects to generate over $500 million from optical products in the future.
- Cellebrite's Market Advantage: Cellebrite serves over 60,000 law enforcement agencies across 150 countries, achieving a 21% growth in annual recurring revenue and a 32% free cash flow margin in its latest quarter, establishing a strong competitive position in digital evidence processing.
- TransMedics' Innovative Healthcare: TransMedics' Organ Care System revolutionizes organ transplantation with real-time perfusion technology, reporting a 21% year-over-year revenue increase to $173.9 million in Q1, and expects annual revenue between $727 million and $757 million, showcasing its unique competitive edge in the medical device sector.
- Investment Potential Analysis: These three companies, while not currently dominating financial headlines, possess significant long-term investment value due to their technological innovations and market demand, particularly in the rapidly evolving fields of AI and healthcare technology.
See More
Strong Start for June Stocks, Focus on Three Tech Giants
- Profitability Highlight: Micron Technology (MU) boasts a 41.5% net profit margin over the past 12 months, with an expected earnings growth rate of 619.8% this year, showcasing its strong competitive position in the memory and storage market, thus attracting investor interest for future growth potential.
- High-Speed Connectivity Solutions: Credo Technology (CRDO) offers high-speed connectivity solutions for Ethernet and PCIe applications, achieving a 31.8% net profit margin over the past year, with an anticipated earnings growth rate of 371.4% this year, indicating significant profitability in the rapidly evolving tech market.
- Automated Testing Systems: Teradyne (TER) excels in developing automated test systems and robotics solutions, achieving a 22.6% net profit margin over the past year, with an expected earnings growth rate of 79% this year, reflecting strong growth potential in the automation sector.
- Investment Strategy Effectiveness: Zacks' stock-picking strategies have outperformed the S&P's average gain of 7.7% per year since 2000, with average gains of 48.4%, 50.2%, and 56.7%, demonstrating their effectiveness and attractiveness in the market.
See More
Dow Jones Rises Amid Ongoing U.S.-Iran Talks; Celestica Sees Major Movement
- Dow Jones Rises: The Dow Jones index climbed on Tuesday amid ongoing U.S.-Iran talks, reflecting market optimism regarding diplomatic progress, which could enhance investor confidence and drive further stock market gains.
- Celestica's Major Movement: Celestica's stock experienced significant fluctuations, potentially linked to its latest earnings report or market dynamics, which may attract short-term traders and impact its shareholder structure.
- Nvidia's Decline: Nvidia's stock fell, likely due to market concerns about its future performance, especially in the context of increasing competition, which could affect its market share and investor confidence.
- Market Sentiment Shifts: Overall market sentiment fluctuated due to international political dynamics, prompting investors to monitor the progress of negotiations in the coming days to assess potential impacts on the stock market.
See More
Solstice and Core Scientific See Active Options Trading
- Solstice Options Volume: Solstice Advanced Materials Inc (Ticker: SOLS) saw options trading volume of 18,645 contracts today, representing approximately 1.9 million shares, which is about 79.3% of its average daily trading volume of 2.4 million shares over the past month, indicating heightened market interest in its future performance.
- High Volume Contracts: The $65 strike put option for SOLS was particularly active, with 15,892 contracts traded today, equating to approximately 1.6 million shares, reflecting investor expectations regarding potential downside risks for the stock.
- Core Scientific Options Activity: Concurrently, Core Scientific Inc (Ticker: CORZ) recorded options trading volume of 113,081 contracts, representing about 11.3 million shares, which accounts for 68.8% of its average daily trading volume of 16.4 million shares over the past month, showcasing strong market interest in its stock.
- Key Contract Insights: Among CORZ options, the $40 strike call option saw a trading volume of 25,119 contracts, approximately 2.5 million shares, indicating investor confidence in the stock's potential upside, which may influence its short-term price movements.
See More
